Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on March 8, 2019. The filing serves to disclose new forms of award agreements approved by the Compensation and Management Development Committee of the Board of Directors under the company's 2012 Stock Award and Incentive Plan, in connection with the regular annual compensation cycle.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly administrative regarding executive compensation agreements and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this document. The primary change disclosed is the approval and filing of new standard forms for equity-based compensation awards for the 2019-2021 period.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the execution of the annual compensation cycle.
Key Facts for Investors to Verify
- The filing includes six new exhibit forms (10.1 through 10.6) detailing specific award agreements.
- Awards include Performance Share Units (2019-2021), Market Share Units, and various Restricted Stock Units (RSUs).
- RSU agreements feature different vesting schedules: one-year cliff, two-year cliff, four-year, and five-year vesting.
- Specific RSU agreements include post-vest holding periods (e.g., two-year holding period for one-year cliff vesting).
- All awards are governed by the Bristol-Myers Squibb Company 2012 Stock Award and Incentive Plan.